Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Total Current Liabilities (2016 - 2025)

Cumberland Pharmaceuticals' Total Current Liabilities history spans 16 years, with the latest figure at $36.7 million for Q4 2025.

  • For Q4 2025, Total Current Liabilities rose 16.2% year-over-year to $36.7 million; the TTM value through Dec 2025 reached $36.7 million, up 16.2%, while the annual FY2025 figure was $36.7 million, 16.2% up from the prior year.
  • Total Current Liabilities for Q4 2025 was $36.7 million at Cumberland Pharmaceuticals, up from $24.3 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $36.7 million in Q4 2025 and bottomed at $17.9 million in Q3 2021.
  • The 5-year median for Total Current Liabilities is $25.3 million (2022), against an average of $25.6 million.
  • The largest annual shift saw Total Current Liabilities decreased 25.03% in 2021 before it skyrocketed 48.24% in 2022.
  • A 5-year view of Total Current Liabilities shows it stood at $19.3 million in 2021, then surged by 48.24% to $28.6 million in 2022, then decreased by 4.38% to $27.3 million in 2023, then grew by 15.71% to $31.6 million in 2024, then rose by 16.2% to $36.7 million in 2025.
  • Per Business Quant, the three most recent readings for CPIX's Total Current Liabilities are $36.7 million (Q4 2025), $24.3 million (Q3 2025), and $24.0 million (Q2 2025).